Franck Morschhauser, MD, PhD

Centre Hospitalier Universitaire de Lille, University Lille, France

N/A

Poster(s):

• 2005 - A phase 1 study evaluating PRT2527, a potent and highly selective CDK9 inhibitor, in patients with select relapsed/refractory B-cell malignancies